|
 |
ExemestaneThis page contains recent news articles, when available, and an overview of Exemestane but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Exemestane (when available) aromatase is an enzyme that converts hormones to estrogen in the body's adrenal glands. The aromatase inhibitors (AIs) are drugs that reduce estrogen levels by blocking the action of aromatase in the adrenal glands. The selective AIs (SAIs) selectively reduce levels of estrogen without interfering with levels of other steroid hormones that are produced by the adrenal gland. Drugs in this class include anastrozole (ArimidexÆ), letrozole (FemaraÆ) and exemestane (AromasinÆ). For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. Mechanism Of Action: Breast cancer cell growth may be estrogen-dependent. Aromatase (exemestane) is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breast cancer. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation, an effect also known as "suicide inhibition". Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme. News Articles on Exemestane Upfront exemestane, tamoxifen/exemestane equal for HR-positive breast cancer - Dec 13, 2009 Upfront use of the aromatase inhibitor exemestane alone or the use of tamoxifen followed by exemestane both appear to be viable treatment options for ... HemOncToday Exemestane for 5 Years Not Superior to Tamoxifen Followed by Exemestane for ... - Dec 11, 2009 In reporting the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial, Daniel Rea, MD, University of Birmingham, Birmingham, United Kingdom, said, ... DG News Two strategies for breast cancer recurrence may be equal - Dec 23, 2009 Researchers presented the late breaking five-year data from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) trial at the San Antonio Breast Cancer ... Cancerfacts.com Exemestane Therapy Show Unfavourable Changes in Lipid Profile: Presented at SABCS - Dec 14, 2009 SAN ANTONIO, Tex -- December 14, 2009 -- Postmenopausal women with oestrogen-positive breast cancer who are treated with exemestane appear to ... DG News AstraZeneca's Phase III Cancer Drug Faslodex Study Shows Positive Results - Update - Dec 10, 2009 However, other study, Tamoxifen, Exemestane, Adjuvant, Multicenter study did not show a difference in disease free survival in women who took Aromasin for ... RTT News Pfizer updates trial results for Aromasin in switch & upfront settings - Dec 15, 2009 Pfizer announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor ... pharmabiz.com Pfizer reveals updated trial results for Aromasin - Dec 14, 2009 Pfizer this week revealed that its breast cancer treatment Aromasin (exemestane tablets) has been shown to reduce the chances of the recurrence of the ... Zenopa Common Drug May Prevent Bone Loss from Breast Cancer Treatment - Dec 10, 2009 Currently, there are three AI's approved by the US FDA: Anastrazole (Arimedex), exemestane (Aromasin), and letrozole (Femara). Dr. Adam Brufsky, MD PhD, ... eMaxHealth Nexavar to make breast cancer drugs work longer - Dec 12, 2009 Aromatase inhibitors include anastrozole, made by AstraZeneca under the brand name Arimidex, and exemestane, made by Pfizer Inc, under the brand name ... TopNews United States Treatment Updates - Dec 23, 2009 In San Antonio this year, scientists reported whether the women who initially started on the aromatase inhibitor Aromasin (exemestane) did better than the ... Curetoday.com (press release) US Oncology Research Network Participates in Seven Oral Clinical Studies ... - Dec 17, 2009 10, regarding the five-year analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive ... PR-CANADA.net (press release) Nya intressanta data för Aromasin vid adjuvant behandling av bröstcancer - Dec 17, 2009 Resultat frÃ¥n TEAM-studien (Tamoxifen, Exemestane, Adjuvant, Multicenter) efter en median uppföljningstid pÃ¥ 5,1 Ã¥r visade ingen skillnad i frÃ¥ga om ... MyNewsdesk (pressmeddelande) Confederação de atletismo confirma doping de mais dois brasileiros - Oct 19, 2009 Os dois atletas foram pegos pelo uso das substâncias proibidas Exemestane (Metabólitos) e Boldenona (Metabólitos). Eles foram comunicados em 16 de setembro ... Zero Hora Aromasin nel trattamento del tumore al seno a insorgenza precoce - Nov 4, 2009 I dati clinici hanno mostrato i benefici sulla sopravvivenza passando a Exemestane dopo 2-3 anni.di terapia con Tamoxifene. Su un totale di 4.742 pazienti, ... XagenaSalute Doping de Daiane se soma a casos ocorridos também no atletismo em 2009 - Oct 30, 2009 ...encontrada em produtos veterinários e comumente usada em cavalos, e exemestane, utilizada para atenuar os efeitos colaterais da primeira, ... O Globo Letrozolo nel cancro mammario - Oct 23, 2009 Tuttavia in questi ultimi anni si sono imposti gli inibitori dell'aromatasi (anastrozolo, letrozolo, exemestane). I risultati dello studio ATAC [1] sembrano ... Pillole.org Breast cancer drug 'cuts deaths' - Feb 13, 2007 Exemestane, sold under the brand name Aromasin, is in a class of drugs called ... Tamoxifen interferes with the action of oestrogen, while exemestane ... BBC News Hormone therapy fights spread of breast cancer - Dec 14, 2008 Women given the aromatase inhibitor exemestane after surgery were 19% less ... Exemestane, marketed as Aromasin, works by shutting off production of the ... Telegraph.co.uk Breast cancer prevention study spotlights debate over drug trials - Apr 3, 2005 She doesn't know whether it's the drug exemestane or a sugar pill. ... Exemestane, which is sold by Pfizer as Aromasin, is approved for treating breast ... USA Today Two-drug treatment gives new cancer hope - Jun 5, 2006 Some patients with arthritis who took exemestane reported that their arthritis became worse. The drug, made by Pfizer under the name Aromasin, ... Telegraph.co.uk Exemestane after tamoxifen as adjuvant hormonal therapy in … - Apr 10, 2006 Recent studies have shown that administering the aromatase inhibitor exemestane after 2–3 years of tamoxifen therapy significantly improves disease-free ... Nature.com Aromasin after tamoxifen ups breast cancer survival - Dec 18, 2006 The finding shows that Aromasin, known technically as exemestane, ... Women taking exemestane were 50 percent less likely to see a recurrence of breast ... Reuters Study of Breast Cancer Pill Raises Hopes and Concerns - May 22, 2005 Exemestane in particular may turn out to protect bone, Goss said. "People who are expressing concern about this really have to wait for the data rather than ... Pay-Per-View - Washington Post - ProQuest Archiver Exemestane: A milestone against breast cancer.(Drug Review) - Apr 1, 2007 Rapid advances in the treatment of breast cancer, especially in the form of hormone therapy have truly increased the hope of longer and better disease-free ... Free with registration - Journal of Postgraduate Medicine - AccessMyLibrary.com Hope for women as anti-cancer drug wins approval - May 23, 2006 Nice's stance paves the way for a full recommendation in November of Femara (letrozole), Aromasin (exemestane) and Arimidex (anastrozole) for ... Times Online Major breast cancer study begins - Mar 30, 2005 Half will receive exemestane and the other half will receive a placebo. ... She feels no real side-effects — exemestane can cause mild nausea and hot ... Globe and Mail To switch or not to switch: implications of sequencing adjuvant... - Mar 20, 2007 ...(2007) Survival and safety of exemestane versus tamoxifen after 2–3 years' ... To determine whether switching to exemestane for 2–3 years following 2–3 ... Nature.com NHS offers breakthrough drugs for breast cancer - Aug 11, 2006 In June the landmark Intergroup Exemestane Study also found that switching to Aromasin cut the risk of death by 17 per cent compared with remaining on ... Times Online Breast cancer drugs gap 'widens' - Nov 16, 2005 Aromasin, also known as exemestane, is claimed to reduce the risk of breast cancer coming back by a third and of cancer in the other breast by half. ... BBC News Learn about Exemestane from Consumer Reports Health. - Jan 3, 2007 Exemestane is used to treat early breast cancer in women who have experienced menopause (change of life; end of monthly menstrual periods) and who have ... consumerreports.org Exemestane May Improve Survival after Tamoxifen Therapy - Apr 30, 2008 NEW YORK APR 30, 2008 (Reuters Health) - In women with early-stage, hormone receptor-positive breast cancer, extended therapy with the steroidal aromatase ... Cancerpage.com A trial for breast cancer prevention - Apr 14, 2005 Three medical centers involved in Goss's trial have begun tests of the aromatase inhibitor exemestane. More than 30 other sites, in the United States, ... New York Times New breast cancer drugs on NHS - Nov 22, 2006 Research carried out by NICE showed that by switching to exemestane, a type of AI, after two to three years of tamoxifen treatment the risk of cancer ... BBC News Fulvestrant, Exemestane Show Equivalent Survival in Relapsed … - Dec 16, 2007 By John Gever. SAN ANTONIO, TX -- December 16, 2007 -- Breast cancer patients who relapse on aromatase inhibitor therapy survive as long with fulvestrant as ... DG News Hutch study to test breast-cancer prevention - Jun 1, 2005 The drug, exemestane, already is used to prevent recurrence of the disease. ... If the clinical trial shows that exemestane can prevent the cancer, ... Seattle Times Switching to Exemestane Ups Disease-Free Survival in Early Breast … - Jun 6, 2006 June 6, 2006 (Atlanta) — Patients with early breast cancer who switch from tamoxifen (Nolvadex, AstraZeneca) to exemestane (Aromasin, Pfizer) live longer ... Medscape … of a Potent Aromatase Inhibitor, Aromasin (Exemestane), in Young... - Mar 1, 2008 Exemestane (Aromasin) is a potent and selective irreversible aromatase inhibitor. ... Exemestane suppressed plasma estradiol comparably with either dose [25 ... Journal of Clinical Endocrinology and... … Symptoms Vary with Tamoxifen or Exemestane for Breast Cancer - Nov 14, 2007 NEW YORK NOV 14, 2007 (Reuters Health) - Among postmenopausal women receiving adjuvant therapy for early breast cancer women, exemestane is associated with ... Cancerpage.com … Rates Similar Between Tamoxifen and Exemestane: Presented at SABCS - Dec 13, 2005 By Ed Susman. SAN ANTONIO, TX -- December 13, 2005 -- Researchers said that fracture rates are similar after 2 years of treatment with tamoxifen or ... DG News Natco launches breast cancer drug - Dec 7, 2007 Natco Pharma Ltd has launched Exemestane, a niche product used in the ... Available as 25 mg tablets, Exemestane is used in the treatment of breast cancer ... Hindu Business Line Can exemestane prevent breast cancer? - May 15, 2005 By Tony Craig. Hormone replacement therapy has taken a U-turn since it was first hailed as a wonder drug. Ten years ago we were prescribing estrogen ... National Review of Medicine Exemestane May Help Downgrade Tumours Scheduled for Mastectomy … - Mar 27, 2006 By Paula Moyer. NICE, FRANCE -- March 27, 2006 -- The aromatase inhibitor exemestane (Aromasin(R)) could make breast-conserving surgery possible in breast ... DG News Pfizer Announces Results from Trial of AROMASIN in Postmenopausal … - Dec 11, 2008 Pfizer today announced results from a first planned analysis of the TEAM (Tamoxifen, Exemestane, Adjuvant, Multicenter) trial. TEAM was originally designed ... International Business Times Switch to exemestane extends early breast cancer survival.(Tamoxifen ... - Jul 1, 2006 ATLANTA -- Postmenopausal women with early-stage hormone-receptive breast cancer who have done well on 2-3 years of tamoxifen therapy have significantly ... Free with registration - Family Practice News - AccessMyLibrary.com Pharmac to fund breast cancer drug - Aug 12, 2007 Under a new agreement Exemestane will be fully funded from August 1 without the need for a special authority approval. Pharmac medical director Dr Peter ... TVNZ FDA Approves Pfizer's Aromasin (Exemestane Tablets) for Adjuvant … - Oct 5, 2005 NEW YORK, NY -- October 5, 2005 -- Pfizer Inc said today that it has received approval from the US Food and Drug Administration (FDA) to market Aromasin(R) ... DG News CLOSER LOOK RESEARCH FINDINGS - Feb 19, 2007 Patients who switched to exemestane reduced their risk of disease recurrence ... Furthermore, women who switched to exemestane had a 15% lower risk of dying ... $2.95 - Milwaukee Journal Sentinel - NewsBank Exemestane Becomes the First And Only Aromatase Inhibitor for... - May 17, 2006 MONTREAL, CANADA -- May 17, 2006 -- Pfizer Canada today announced that Aromasin (exemestane tablets), has been granted a Notice of Compliance with ... DG News Breast Cancer Guidelines Confirm Central Role Of 'Switch Strategy' - Aug 7, 2007 Switching from tamoxifen to exemestane has the potential to save lives among ... Exemestane, one of the aromatase inhibitors, has been proven to offer an ... Medical News Today - Medical News Today (press release) Health Watch Health Watch - Preventing Breast Cancer - Dec 22, 2008 Dr. Eisen says the drug, called exemestane (Aromasin), lowers estrogen levels by more than 95-percent. "Higher levels of estrogen have been linked to ... go.com … of women treated with adjuvant exemestane therapy not significantly... - Nov 8, 2005 2005 NOV 8 - (NewsRx.com) -- The lipidemic profile of women treated with adjuvant exemestane therapy does not appear to be significantly altered following ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Exemestane (Systemic). - Feb 1, 2006 Exemestane(ex-uh-MESS-tane )is a medicine that is used to treat breast cancer in women whose disease has progressed while they were taking tamoxifen( ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Extended Adjuvant Exemestane Cuts Breast Cancer Relapse: Presented … - Mar 19, 2007 By Joanna Lyford. ST. GALLEN, SWITZERLAND -- March 19, 2007 -- Extended adjuvant therapy with exemestane reduces the risk of late breast cancer relapse in ... DG News Exemestane (Systemic).(Drug overview) - May 1, 2006 Exemestane(ex-uh-MESS-tane )is a medicine that is used to treat breast cancer in women whose disease has progressed while they were taking tamoxifen( ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Local study testing drug to prevent breast cancer - Oct 9, 2005 Exemestane, also known as Aromasin, was approved by federal regulators in 1999 ... Exemestane is part of a family of drugs called aromatase inhibitors that ... Boston Globe Taking Exemestane from Consumer Reports Health. - Jan 3, 2007 Exemestane may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:. Some side effects can be serious. ... consumerreports.org Low vitamin D plus exemestane tied to bone loss: the connection … - Jul 15, 2006 ATLANTA -- Vitamin D supplementation should be considered for postmenopausal breast cancer patients treated with aromatase inhibitors, Dr. Per E. Lonning ... Free with registration - OB GYN News - AccessMyLibrary.com International Approvals: Aromasin, IPM Wound Gel, Risperdal Consta - Sep 19, 2005 19, 2005 — The European Commission has approved exemestane tablets for the ... In the study, women who switched to exemestane after two or three years of ... Medscape Two Adjuvant Treatments for Breast Cancer Earn Their Keep - Jun 26, 2007 Cost savings in the exemestane group for reduced cancer recurrence were ... The incremental cost-effectiveness ratio for exemestane was $28119 per life year ... MedPage Today Critics: Price of cancer-drug test too high - May 5, 2005 The debate over a drug called exemestane revolves around twin questions, ... Even if it could, might exemestane also deliver still-unknown side effects that ... $2.95 - Sacramento Bee - NewsBank St Gallen guidelines recommend switch from tamoxifen to an AI for... - Aug 13, 2007 Exemestane was the first AI to receive approval in the switch setting. ... Furthermore, switching to exemestane has also been proven to have no significant ... Free with registration - Pharma Marketletter - AccessMyLibrary.com … cancer prevention study reveals encouraging news for Exemestane - Dec 13, 2008 In addition to exemestane, all the study participants received calcium carbonate ... The exemestane study continues with endpoints including bone density ... Eureka! Science News Breast Cancer Prevention Study Spotlights Debate Over Drug Trials - Apr 4, 2005 She doesn't know whether it's the drug exemestane or a sugar pill. ... Exemestane, which is sold by Pfizer as Aromasin, is approved for treating breast ... RedOrbit How to take Exemestane from Consumer Reports Health. - Jan 3, 2007 ...tell your doctor and pharmacist if you are allergic to exemestane or any other medications. tell your doctor and pharmacist what other prescription and ... consumerreports.org International Approvals: Keppra, Menactra, Aromasin - May 22, 2006 On May 12, Health Canada approved a new indication for exemestane (Aromasin ... The approval was based on data from the phase 3 Intergroup Exemestane Study ... Medscape Netherlands Corporate News - Borstkanker richtlijnen bevestigen... - Mar 8, 2007 Switching from tamoxifen to exemestane has the potential to save lives among ... Exemestane, one of the aromatase inhibitors, has been proven to offer an ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Data From The Team Study Confirm Importance Of Aromasin® In … - Jun 5, 2007 In the IES, exemestane demonstrated an overall survival benefit " the ... The data also demonstrated that women who switched to exemestane experienced ... Medical News Today - Medical News Today (press release) Preventing Breast Cancer |West Palm Beach News, South Florida … - Oct 30, 2007 The drug, exemestane (Aromasin), works by lowering the amount of estrogen in the body. The drug can actually lower estrogen levels by more than 95-percent. ... WPTV Letrozole Reduces Risk Of Breast Cancer Recurrence And Metastasis … - Mar 12, 2008 Exemestane was well tolerated by most of the women. ... "Benefit from Exemestane as Extended Adjuvant Therapy Following Five Years of Adjuvant Tamoxifen: ... Medical News Today - Medical News Today (press release) Exemestane now funded - Dec 8, 2007 Women with breast cancer now have another funded drug treatment available. PHARMAC will be funding the drug Exemestane from the August 1. ... Newstalk ZB Aromatase Inhibitors Have Different Cardiovascular Safety Profiles: … - Nov 2, 2005 The BIG 1-98 trial compared letrozole and tamoxifen in 8028 women, and the IES-trial compared exemestane and tamoxifen in 4742 women. ... DG News Switch to exemestane beneficial in early breast ca.(Women's Health)(Br... - Aug 15, 2006 ATLANTA -- Postmenopausal women with early-stage hormone-receptive breast cancer who have done well on 2-3 years of tamoxifen therapy have improved survival ... $4.95 - Internal Medicine News - ECNext AstraZeneca drug shows promise in breast cancer - Jan 2, 2007 The 'Efect' trial compared Faslodex with exemestane (a Pfizer drug marketed as Aromasin), with the AstraZeneca drug showing slightly higher levels of ... Hays Pharma Breast cancer drugs (anastrozole, exemestane and letrozole) - Nov 8, 2006 Final draft approval for new drugs to tackle early stage breast cancer in postmenopausal women has been given by the government's health watchdog. ... Private Healthcare UK Women Sought for Study of Drug That May Block Cancer - Dec 19, 2005 A previous study showed that Exemestane prevented new cancers in the opposite ... Another study found that Exemestane was more effective than the standard ... RedOrbit Breakthrough for cancer treatment - Jun 6, 2006 The new data from the Intergroup Exemestane Study (IES) provide the first proof that women ... Women given aromasin, which has the generic name exemestane, ... Belfast Newsletter Breast Cancer Therapies Appear to Advance Cognitive Decline - Jul 12, 2007 Patients were randomized to receive tamoxifen (20 mg/day) or exemestane (25 ... Both tamoxifen and exemestane users reported significantly more memory ... Medscape Breast Cancer Guidelines Confirm Central Role of 'Switch Strategy'; … - Aug 2, 2007 Switching from tamoxifen to exemestane has the potential to save lives among ... Exemestane, one of the aromatase inhibitors, has been proven to offer an ... Genetic Engineering News - Genetic Engineering News (press release) Aromasin - Exemestane - Medical Drug - Nov 5, 2007 Aromasin is an aromatase inactivator which works by reducing the supply of oestrogen to cancer cells. This stops the growth of breast cancer cells which are ... Virtual Medical Centre - The Virtual Medical Centre San Antonio Breast Cancer Symposium. - Dec 15, 2006 Today's momentum came in as Results of two studies evaluating the hormonal therapy Aromasin (exemestane tablets) and the chemotherapy Ellence (epirubicin ... Free with registration - M2 Presswire - AccessMyLibrary.com New Breast Cancer Guidelines Drop Tamoxifen as Single Agent in … - Mar 18, 2005 ..."The panel believes the three selective aromatase inhibitors -- anastrozole, letrozole and exemestane -- have similar anti-tumor efficacy and similar ... DG News Article: Switch to exemestane beneficial in early breast ca.(Women's ... - Aug 15, 2006 Switch to exemestane beneficial in early breast ca.(Women's Health)(Brief article)(Clinical report) ... find Internal Medicine News articles. Pay-Per-View - Internal Medicine News - HighBeam Research exemestane Pfizer supplemental approval, EU (breast cancer). - Sep 19, 2005 On 13 September 2005 Pfizer announced that exemestane (AROMASIN) has been approved in the EU ... exemestane, FCE 24304, PNU 971, ONC 0028, AROMASIN, L2B3, ... Pay-Per-View - R & D Focus Drug News - Factiva, from Dow Jones Breast Ca outcomes seem aided by anastrozole switch.(Women's Health) - Feb 15, 2005 In a separate presentation, Charles Coombes, MD, presented an update on the Intergroup Exemestane Study (IES), in which 4740 postmenopausal breast cancer ... Pay-Per-View - Internal Medicine News - Factiva, from Dow Jones New drugs add to armoury in fight against breast cancer. - Aug 14, 2006 In June, the landmark intergroup exemestane study also found that switching to Aromasin cut the risk of death by 17 per cent compared with remaining on ... Free with registration - Europe Intelligence Wire - AccessMyLibrary.com Postmenopausal Breast Cancer Survivors Face Higher Osteoporosis Risk - May 11, 2005 Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, are used as adjuvant therapy to suppress plasma estradiol, estrone, ... Cancerpage.com Article: Low vitamin D plus exemestane tied to bone loss: the... - Jul 15, 2006 Low vitamin D plus exemestane tied to bone loss: the connection between vitamin D insufficiency and breast cancer has not been fully examined. Pay-Per-View - OB GYN News - HighBeam Research Exemestane (Aromasin, Pfizer) was approved for adjuvant treatment of ... - Nov 1, 2005 Exemestane (Aromasin, Pfizer) was approved for adjuvant treatment of postmenopausal women. Exemestane (Aromasin, Pfizer) was approved for adjuvant treatment ... $9.94 - Formulary - Alacra Store FDA Approves Aromasin(R) for Adjuvant Treatment of Early Breast … - Oct 10, 2005 The approval was based on the Intergroup Exemestane Study (IES) which showed that patients who switched to Aromasin after two-to-three years of tamoxifen, ... Medical News Today - Medical News Today (press release) Osteoporosis Drug Seems to Shrink Breast Tumors - Dec 12, 2008 ..."Exemestane is very effective at preventing recurrences," said Dr. Stephen ... Exemestane, like other aromatase inhibitors, blocks production of estrogen, ... Washington Post Changing Therapy Sequence does not Improve Survival for Inflammatory ... - Jun 19, 2006 June 3, 2006 - New data from the Intergroup Exemestane Study (IES) showed for the first time today that hormone sensitive postmenopausal early breast cancer ... SeniorJournal.com European parliament takes on CIP scheme - Jun 12, 2006 Data presented by the Intergroup Exemestane Study show that women who switched to Aromasin after two to three years on tamoxifen have a 30% lower risk of ... ICIS Pfizer Receives European Approval to Market Aromasin(R) for Adjuvant ... - Sep 13, 2005 The approval was based on the Intergroup Exemestane Study (IES) that showed patients who switched to Aromasin after two to three years of tamoxifen had a 31 ... $4.95 - PR Newswire - ECNext Behind the Headlines: Could breast cancer drug save lives?(new drug... - Feb 23, 2007 Switching to exemestane for two years reduced this risk to 50 per cent Researchers ... Exemestane is one of a group of drugs known as aromatase inhibitors. ... Free with registration - GP - AccessMyLibrary.com Aromasin approved as adjuvant.(PRODUCTS)(Brief Article) - Dec 1, 2005 Aromasin (exemestane tablets) is approved as an adjuvant treatment for post-menopausal women with estrogen receptor-positive breast cancer who have received ... Free with registration - OB GYN News - AccessMyLibrary.com Breast Cancer; Use of aromatase inhibitors in management of breast … - Dec 27, 2005 ..."Clinical trials of aromatase inhibitors including exemestane, an orally active steroidal aromatase inactivator, have demonstrated significant improvements ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Side effects vary by breast cancer maintenance therapy - Nov 15, 2007 NEW YORK (Reuters Health) - Among postmenopausal women receiving adjuvant therapy for early breast cancer, exemestane is associated with fewer hot flashes ... Reuters India Breast Cancer Survival Rates Improved By Novel Drug Sequence, Say … - Feb 16, 2007 The new paper shows that switching to a drug called exemestane, ... The Intergroup Exemestane Study (IES), which involved women from 37 different countries, ... Medical News Today - Medical News Today (press release) Breast Cancer; Fulvestrant compared to anastrozole for treatment of … - Sep 20, 2005 ..."The third-generation AIs letrozole and exemestane also demonstrate efficacy after tamoxifen failure," wrote D. Dodwell and colleagues. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones NewsWire-ë³´ë?„ìž?료 í†µì‹ ì‚¬ 뉴스와ì?´ì–´ - Nov 14, 2008 ...병용 ìœ ë¬´ ì‹œ FaslodexTM를 Exemestaneê³¼ 비êµ? í?‰ê°€í•˜ê¸° 위하여 í•œêµì•„스트ë?¼ì œë„¤ì¹´ ê°€ 삼성서울병ì›? 등ì—? ì?˜ë¢°í•˜ì—¬ 실시하는 ì?˜ì•½í’ˆ ìž„ìƒ?시험계íš? 등 7ê±´ê³¼, ... 뉴스와ì?´ì–´ Researchers seek volunteers for breast cancer study - Trial to... - Dec 15, 2005 ..."We will be evaluating the effects of exemestane on women who are at least 35 ... Exemestane is manufactured by Pfizer Inc. and was approved by the US Food ... Pay-Per-View - Star-Ledger - Factiva, from Dow Jones Article: New drug is life saver.(News) - Daily Record (Glasgow,... - Jun 5, 2006 Article: Pfizer Releases New Data from the Intergroup Exemestane . ... The International Exemestane Study (IES) randomized 4742 patients with breast cancer ... Pay-Per-View - Daily Record - HighBeam Research Celecoxib Doesn"t Improve Breast Cancer Therapy Response - Apr 1, 2008 They were randomized to therapy with exemestane 25 mg daily with or without ... Clinical benefit was observed in 48.98% of the assessable exemestane ... Cancerpage.com Small Difference in Lipid Effect Seen Among Aromatase Inhibitors - Dec 12, 2005 Initial results from the Letrozole, Exemestane, and Anastrozole Pharmacodynamics ... For women receiving exemestane, the percentage change from baseline of ... Medscape Preventing Breast Cancer -- In-Depth Doctor's Interview - Dec 6, 2007 Dr. Eisen: Exemestane is part of a class of drugs called the aromatase inhibitors and it ... What side effects are associated with drugs like exemestane? ... Ivanhoe Broadcast News FDA Approvals: Aromasin, Norvir, Helixate/Kogenate FS - Oct 14, 2005 On Oct. 5, the FDA approved a new indication for exemestane (Aromasin ... The approval was based on data from the phase 3 Intergroup Exemestane Study (IES) ... Medscape Carbamazepine Oral: Dosage, Uses and Warnings - Oct 4, 2005 PATIENT MANAGEMENT: The US manufacturer of exemestane recommends that patients ... 1) The dosage of exemestane may need to be adjusted if carbamazepine, ... Medscape Osteoporosis Drug Seems to Shrink Breast Tumors - Dec 10, 2008 ..."Exemestane is very effective at preventing recurrences," said Dr. Stephen ... Exemestane, like other aromatase inhibitors, blocks production of estrogen, ... Forbes The evolving role of aromatase inhibitors in the treatment of early... - Jul 15, 2005 In the Intergroup Exemestane Study (IES), an AI given in sequence after tamoxifen ... (2004) A randomized trial of exemestane after two to three years of ... Nature.com ìœ ë°©ì•”ì¹˜ë£Œì œ '파슬로ë?±ìŠ¤' êµë‚´ 허가 - Oct 26, 2007 EFFECT(Evaluation of Faslodex vs Exemestane Clinical Trial) 연구ì—?ì„œ ì?´ì „ì—? 호르몬 치료를 ë°›ê³ ì§ˆë³‘ì?´ 진행ë?œ 여성ì—?게 파슬로ë?±ìŠ¤ë¡œ 치료한 ê²°ê³¼ 35.1%ì?˜ 환ìž? ... 머니투ë?°ì?´ Cancer drugs get draft approval - Aug 10, 2006 The inhibitors - anastrozole (Arimidex), exemestane (Aromasin) and letrozole ... In June, the Intergroup Exemestane Study also found that switching to ... BBC News Drug Criteria & Outcomes: New FDA Approvals. - Dec 1, 2005 New indication for exemestane tablets (Aromasin) by Pfizer. The FDA has approved exemestane tablets (Aromasin) for adjuvant treatment of postmenopausal ... Free with registration - Drug Formulary Review - AccessMyLibrary.com … : il passaggio da Tamoxifene ad Exemestane aumenta la sopravvivenza - Jun 29, 2006 Giovedì 29 Giugno 2006 - Lo studio IES ( Intergroup Exemestane Study ) ha ... Exemestane non dovrebbe essere impiegato nelle donne in post-menopausa che ... XagenaSalute PrensaLibre.com - Últimas noticias - Feb 13, 2007 Londres - Numerosas vidas pueden salvarse si las mujeres que se recuperan de un cancer de mama cambian el farmaco Tamoxifen por otro llamado Exemestane o ... Prensa Libre - Prensa Libre (Guatemala) American Society of Clinical Oncology (ASCO) 2006: 1 - Jun 19, 2006 The risk of death was reduced by 15% in the exemestane switch group when ... The survival rate was 89.9% in the exemestane group, compared to 88.7% in the ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones Exemestane dopo tamoxifene - Dec 20, 2007 Dopo 2-3 anni di tamoxifene il passaggio ad exemestane migliora la sopravvivenza libera da malattia in donne con pregresso cancro mammario invasivo. ... Pillole.org Brand Names/Synonyms: Exemestane is also known by the following brand names and/or synonymsAromasin; EXEMESTANE; Exemestance; Exemestane; Exemestane [Inn]; Exemestane [Usan:Inn:Ban]; Exemestano [Inn-Spanish]; Exemestanum [Inn-Latin] Drug Category: Exemestane is categorized under the following by the FDA: Antineoplastic Agents; ATC:L02BG06 Dosage Forms: tablets Absorption: 42% Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 10,13-dimethyl-6-methylidene-7,8,9,10,11,12,13,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
